Pharmaceuticals

Abrysvo Or Arexvy Market 2026–2030: Forecast, Innovation, and Competitive Trends

March 5, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the abrysvo or arexvy market from 2026–2035 with trusted insights from The Business Research Company

What market expansion outlook does the Abrysvo Or Arexvy Market show for the 2026–2030 period?

The historical period’s growth was primarily driven by the unfulfilled demand for RSV vaccines, the expansion of the aging population, the considerable burden posed by respiratory infections, the successful acquisition of regulatory approvals, and a rising level of public health awareness.

Anticipated growth in the upcoming period is linked to an expanding aging population, increasing rates of RSV-related hospitalizations, more comprehensive vaccination guidelines, enhanced accessibility to services via providers, and a stronger emphasis on preventive healthcare. Key trends during this forecast period include a heightened focus on RSV prevention, increased vaccination among older adults, the expansion of immunization programs for adults, vaccine distribution through hospitals and community initiatives, and proactive care strategies for high-risk groups.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=19948&type=smp

What Drivers Are Shaping The Development Of The Abrysvo Or Arexvy Market?

The rising occurrence of respiratory syncytial virus (RSV) infections is projected to boost the expansion of the abrysvo or arexvy market in the future. Respiratory syncytial virus, a common pathogen mainly impacting the respiratory system, causes RSV infections, which typically result in mild cold-like symptoms for most people but can lead to serious health issues in babies, seniors, and those with weakened immune systems. The growing incidence of RSV infections stems from their high contagiousness, recurrent seasonal outbreaks, insufficient population-wide immunity, and heightened vulnerability in groups like infants and the elderly. Abrysvo offers a solution to the prevalence of RSV infections through specific vaccines designed to shield at-risk demographics, including older adults and infants, from severe diseases caused by the respiratory syncytial virus. For example, the Centers for Disease Control and Prevention, a US-based health protection agency, reported in Oct 2024 that the overall hospitalization rate due to RSV hit 3.2 per 100,000 individuals during the 2024-25 season. Consequently, the widespread presence of RSV infections is a key factor propelling the abrysvo or arexvy market’s growth.

Which Segments Are Contributing To The Growth Of The Abrysvo Or Arexvy Market?

The abrysvo or arexvy market covered in this report is segmented –

1) By Clinical Indication: Respiratory Syncytial Virus (RSV) Prevention, Infant Protection

2) By Age Group: Adults (18-59 years), Older Adults (60+ years), Pregnant Individuals (32-36 weeks of gestation)

3) By End User: Healthcare Providers, Pregnant Individuals, High-Risk Adults

How Are New Market Trends Shaping The Landscape Of The Abrysvo Or Arexvy Market?

Leading companies in the abrysvo or arexvy market are concentrating on developing advanced products, such as bivalent prefusion F (RSVpreF) vaccines, to expand protection, enhance safety, and address high-risk populations. Bivalent RSVpreF vaccines are formulations engineered to provide immunity against both major RSV subgroups (RSV-A and RSV-B) by targeting the prefusion state of the fusion (F) protein, which is a key site for neutralizing antibodies. For instance, in October 2024, Pfizer Inc., a US-based pharmaceutical company, obtained U.S. Food and Drug Administration (FDA) approval for ABRYSVO (RSV Vaccine), a bivalent RSV prefusion F (RSVpreF) vaccine, for preventing lower respiratory tract disease in adults aged 18 to 59 at increased risk, thereby extending its indication to the broadest adult population. It remains the only approved RSV vaccine for pregnant individuals between 32 and 36 weeks of gestation to protect infants from birth to 6 months.

Who Are The Top-Performing Companies In The Abrysvo Or Arexvy Market In Recent Years?

Major companies operating in the abrysvo or arexvy market are Pfizer Inc., GlaxoSmithKline plc (GSK)

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/abrysvo-or-arexvy-global-market-report

Which Region Currently Holds The Largest Share Of The Abrysvo Or Arexvy Market?

North America was the largest region in the abrysvo or arexvy market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the abrysvo or arexvy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Abrysvo Or Arexvy Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=19948&type=smp

Browse Through More Reports Similar to the Global Abrysvo Or Arexvy Market 2026, By The Business Research Company

Business Intelligence Bi Vendors Market Report 2026

https://www.thebusinessresearchcompany.com/report/business-intelligence-bi-vendors-global-market-report

Financial Analytics Market Report 2026

https://www.thebusinessresearchcompany.com/report/financial-analytics-global-market-report

Data Lake Market Report 2026

https://www.thebusinessresearchcompany.com/report/data-lake-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795